Related Experiment Videos
Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab
David Chu1, Michelle Stevens, Douglas Edward Gladstone
1Stony Brook University Medical Center, SUNY Stony Brook, HSC, Level 17, Rm 080, Stony Brook, NY 11794-8174, USA.
Abstract:
A 41 year old female with type I cryoglobulinemia, refractory to methylprednisolone, rituximab, and cyclophosphamide complicated by a rising serum viscosity was treated with alemtuzumab. After a cumulative dose of 1,085 mg of alemtuzumab, her serum viscosity decreased to normal. Treatment toxicity was limited to fungal esophagitis responsive to topical therapy. This case demonstrates the potential use of alemtuzumab in the treatment of refractory cryoglobulinemia.
Related Concept Videos
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hypersensitivity Reactions: Cytolytic Reactions